Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H10O3 |
Molecular Weight | 166.1739 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1=CC=CC=C1O
InChI
InChIKey=GYCKQBWUSACYIF-UHFFFAOYSA-N
InChI=1S/C9H10O3/c1-2-12-9(11)7-5-3-4-6-8(7)10/h3-6,10H,2H2,1H3
Molecular Formula | C9H10O3 |
Molecular Weight | 166.1739 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00936https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdfCurator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html
Sources: http://www.drugbank.ca/drugs/DB00936https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdf
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html
Methyl salicylate (or methyl 2-hydroxybenzoate), also known as wintergreen oil, is a natural product and is present in white wine, tea, porcini mushroom Boletus edulis, Bourbon vanilla, clary sage, red sage and fruits including cherry, apple, raspberry, papaya and plum. Methyl salicylate is topically used in combination with methanol and under brand name SALONPAS to temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises. The precise mechanism of action of methyl salicylate is not known, but there is suggested, that it cause dilation of the capillaries thereby increasing blood flow to the area.
Originator
Sources: http://www.casinapioiv.va/content/dam/accademia/pdf/acta18/acta18-szczeklik.pdfhttps://books.google.ru/books?id=iUpwBAAAQBAJ&pg=PT83&lpg=PT83&dq=Methyl+salicylate+Auguste+Andr%C3%A9+Thomas+Cahours&source=bl&ots=nFDf2n2bpT&sig=wAKTDamdc7xWWgRxOrTeokeji8g&hl=ru&sa=X&ved=0ahUKEwj-q8769PzTAhVFfhoKHYEqDgkQ6AEIODAD#v=onepage&q=Methyl%20salicylate%20Auguste%20Andr%C3%A9%20Thomas%20Cahours&f=false
Curator's Comment: first isolated in 1843
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: http://www.drugbank.ca/drugs/DB00936 |
|||
Target ID: CHEMBL230 Sources: http://www.drugbank.ca/drugs/DB00936 |
|||
Target ID: CHEMBL2311236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26101955 |
1.48 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date1.20346562E12 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date1.20346562E12 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date1.20346562E12 |
|||
Palliative | SALONPAS Approved UseTemporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date1.20346562E12 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date1.35501119E12 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date1.35501119E12 |
|||
Primary | Salicylic Acid Approved UseSalicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date1.35501119E12 |
Doses
Dose | Population | Adverse events |
---|---|---|
30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
Other AEs: Redness, Scales... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Redness | 30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
|
Scales | 30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: |
unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/9207195/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
major | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries. | 2001 |
|
Hydroxyl radical adduct of 5-aminosalicylic acid: a potential marker of ozone-induced oxidative stress. | 2001 |
|
Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059. | 2001 Apr |
|
Cyanide-resistant alternative respiration is strictly correlated to intracellular peroxide levels in Acremonium chrysogenum. | 2001 Apr |
|
[Principal constituents from flowering aerial parts of wild pansy]. | 2001 Apr |
|
Evaluation of insulin permeability and effects of absorption enhancers on its permeability by an in vitro pulmonary epithelial system using Xenopus pulmonary membrane. | 2001 Apr |
|
Nitric oxide: comparative synthesis and signaling in animal and plant cells. | 2001 Apr |
|
Sodium salicylate increases CYP2E1 levels and enhances arachidonic acid toxicity in HepG2 cells and cultured rat hepatocytes. | 2001 Apr |
|
Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. | 2001 Apr |
|
Uptake mechanism of valproic acid in human placental choriocarcinoma cell line (BeWo). | 2001 Apr 13 |
|
Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on nitric oxide-induced hydroxyl radical generation in the rat heart. | 2001 Apr 30 |
|
[Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents]. | 2001 Apr 6 |
|
Hereditary palmoplantar keratoderma (four cases in three generations). | 2001 Feb |
|
Estrogenic activity of phenolic additives determined by an in vitro yeast bioassay. | 2001 Feb |
|
Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis. | 2001 Feb |
|
Increased leukotriene production by food additives in patients with atopic dermatitis and proven food intolerance. | 2001 Feb |
|
Ethylene-dependent salicylic acid regulates an expanded cell death response to a plant pathogen. | 2001 Feb |
|
3-Hydroxybenzoic acid as an internal standard for the high-pressure liquid chromatography quantitation of salicylic acid in plants. | 2001 Feb 1 |
|
Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals. | 2001 Feb 1 |
|
A hot pepper cDNA encoding a pathogenesis-related protein 4 is induced during the resistance response to tobacco mosaic virus. | 2001 Feb 28 |
|
Molecular cloning of the nahG gene encoding salicylate hydroxylase from Pseudomonas fluorescens. | 2001 Feb 28 |
|
Characterization of PBZ1, a probenazole-inducible gene, in suspension-cultured rice cells. | 2001 Jan |
|
Non-uniform mapping of stress-induced, motility-related charge movement in the outer hair cell plasma membrane. | 2001 Jan |
|
Increases in the mutation frequency at which fusidic acid-resistant Staphylococcus aureus arise with salicylate. | 2001 Jan |
|
Probenazole induces systemic acquired resistance in Arabidopsis with a novel type of action. | 2001 Jan |
|
Manipulation of salicylate content in Arabidopsis thaliana by the expression of an engineered bacterial salicylate synthase. | 2001 Jan |
|
Microfabrication of individual 200 microm diameter transdermal microconduits using high voltage pulsing in salicylic acid and benzoic acid. | 2001 Jan |
|
Effect of 4-trifluoromethyl derivatives of salicylate on nuclear factor kappaB-dependent transcription in human astrocytoma cells. | 2001 Jan |
|
Free and conjugated benzoic acid in tobacco plants and cell cultures. Induced accumulation upon elicitation of defense responses and role as salicylic acid precursors. | 2001 Jan |
|
Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis. | 2001 Jan 15 |
|
Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism. | 2001 Jan 15 |
|
Quantitative analysis of crystalline pharmaceuticals in powders and tablets by a pattern-fitting procedure using X-ray powder diffraction data. | 2001 Jan 16 |
|
Synthesis and metal binding properties of salicylate-, catecholate-, and hydroxypyridinonate-functionalized dendrimers. | 2001 Jan 5 |
|
Release of salicylic acid, diclofenac acid and diclofenac acid salts from isotropic and anisotropic nonionic surfactant systems across rat skin. | 2001 Jan 5 |
|
Broad-spectrum mildew resistance in Arabidopsis thaliana mediated by RPW8. | 2001 Jan 5 |
|
Combined cryotherapy/70% salicylic acid treatment for plantar verrucae. | 2001 Jan-Feb |
|
Quantitative analysis of hydroxyl radicals in the anterior optic nerve of the cat following transient ischemia. | 2001 Jan-Feb |
|
Interaction of the Arabidopsis receptor protein kinase Wak1 with a glycine-rich protein, AtGRP-3. | 2001 Jul 13 |
|
Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts. | 2001 Jun 1 |
|
The Arabidopsis downy mildew resistance gene, RPP13-Nd, functions independently of NDR1 and EDS1 and does not require the accumulation of salicylic acid. | 2001 Mar |
|
Development of QSARs to investigate the bacterial toxicity and biotransformation potential of aromatic heterocylic compounds. | 2001 Mar |
|
Quantitative analysis of analgoantipyretics in dosage form using planar chromatography. | 2001 Mar |
|
In vivo evidence for accelerated generation of hydroxyl radicals in liver of Long-Evans Cinnamon (LEC) rats with acute hepatitis. | 2001 Mar 1 |
|
Flow-through UV spectrophotometric sensor for determination of (acetyl)salicylic acid in pharmaceutical preparations. | 2001 Mar 23 |
|
ATR-FTIR spectroscopic investigations on the effect of solvents on the permeation of benzoic acid and salicylic acid through silicone membranes. | 2001 Mar 23 |
|
Determination of salicylate, gentisic acid and salicyluric acid in human urine by capillary electrophoresis with laser-induced fluorescence detection. | 2001 Mar 5 |
|
Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. | 2001 May |
|
Asbestos causes apoptosis in alveolar epithelial cells: role of iron-induced free radicals. | 2001 May |
|
Laryngeal oedema caused by accidental ingestion of Oil of Wintergreen. | 2001 May 11 |
|
6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum. | 2001 May 8 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/salicylic-acid.html
The preferable method of use is to apply Salicylic Acid 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for a least five minutes prior to application.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1811921
Salicylic acid inhibited hippuric acid formation in the homogenates obtained from the specimens of human liver with IC50 value 0.19 mM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:08:47 UTC 2023
by
admin
on
Fri Dec 15 15:08:47 UTC 2023
|
Record UNII |
555U6TZ2MV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
JECFA EVALUATION |
ETHYL SALICYLATE
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
||
|
CFR |
21 CFR 172.515
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB15576
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY | |||
|
C041835
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY | |||
|
775
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY | |||
|
ETHYL SALICYLATE
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY | |||
|
DTXSID1021958
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY | |||
|
m5172
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY | Merck Index | ||
|
118-61-6
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY | |||
|
1546423
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY | RxNorm | ||
|
204-265-5
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY | |||
|
SUB13749MIG
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY | |||
|
555U6TZ2MV
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY | |||
|
555U6TZ2MV
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY | |||
|
100000079014
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY | |||
|
8365
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY | |||
|
8209
Created by
admin on Fri Dec 15 15:08:47 UTC 2023 , Edited by admin on Fri Dec 15 15:08:47 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (GC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |